1. Scrip
  2. >>Conferences
  3. >>ASCO

ASCO Data Could Clarify Ocular Toxicity Concerns For ImmunoGen’s Mirvetuximab

Pivotal Trial Results And Pooled Safety Analysis Being Presented

 
• By Alaric DeArment

ImmunoGen may need to mount an aggressive education campaign to get in front of issues like blurred vision and keratopathy, with ocular toxicity being common among antibody-drug conjugates.  

ImmunoGen is presenting data at ASCO on mirvetuximab soravtansine in platinum-resistant FRa-high ovarian cancer • Source: Shutterstock

ImmunoGen, Inc.’s mirvetuximab soravtansine is likely headed for US Food and Drug Administration accelerated approval for a biomarker-driven form of ovarian cancer by the end of the year, on the back of positive data that the company plans to present at the American Society of Clinical Oncology annual meeting. From there, it may face a competitive threat down the line from a drug with the same target from Bristol Myers Squibb Company, along with potential challenges over ocular toxicity.

ImmunoGen is presenting two sets of data for mirvetuximab at the ASCO annual meeting, being held 3-7 June in Chicago,...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from ASCO

In Brief: Sanofi Cements Support For Adagene

 
• By Kevin Grogan

Deal Snapshot: The French drugmaker has been shifting its investments away from cancer to focus on immunology and inflammation but it continues to seek out interesting early-stage oncology assets.

J&J’s Trispecific Antibody For Myeloma Offers Improved Safety, Potency Over Bispecifics

 
• By Alaric DeArment

The drugmaker presented data from its Phase I study of JNJ-79635322 at ASCO and EHA showing a 100% response rate in BCMA- and GPRC5D-naïve patients.

ASCO: Pushing The Frontiers Of ADCs

 
• By Mary Jo Laffler

Antibody-drug conjugates are a major part of the oncology pipeline, and data presented at the American Society of Clinical Oncology meeting highlight the emergence of new technologies.

Innovent Builds Metabolic Pipeline While Retaining Oncology Backbone

 
• By Xu Hu

Innovent presented data on multiple pipeline assets at ASCO, including promising OS results for its first-in-class anti-PD-1/IL-2α-bias bispecific. The Chinese firm is also continuing to build out its metabolic disease portfolio and consider its partnering strategies, its CEO tells Scrip.

More from Conferences